Clomiphene and anti-oestrogens for ovulation induction in PCOS

被引:120
作者
Brown, Julie [1 ]
Farquhar, Cindy
Beck, James [2 ]
Boothroyd, Clare [3 ]
Hughes, Edward [4 ]
机构
[1] Univ Auckland, FMHS, Auckland 1, New Zealand
[2] Univ Newcastle, Jesmond, England
[3] Greenslopes Specialist Ctr, Greenslopes, Australia
[4] McMaster Univ, Dept Obstet & Gynaecol, Hamilton, ON, Canada
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2009年 / 04期
关键词
Anovulation [complications; Contraceptives; Oral; Combined [therapeutic use; Estrogen Antagonists [therapeutic use; Infertility; Female [drug therapy; Polycystic Ovary Syndrome [complications; Randomized Controlled Trials as Topic; Female; Humans; POLYCYSTIC-OVARY-SYNDROME; DEHYDROEPIANDROSTERONE-SULFATE LEVELS; HUMAN CHORIONIC-GONADOTROPIN; RESISTANT ANOVULATORY WOMEN; DOUBLE-BLIND; AROMATASE INHIBITORS; HORMONE SECRETION; CLINICAL-TRIAL; CITRATE; DEXAMETHASONE;
D O I
10.1002/14651858.CD002249.pub4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Back ground Subfertility due to anovulation is a common problem in women. First-line oral treatment is with anti-oestrogens, for example clomiphene citrate, but resistance (failure to ovulate) may be apparent with clomiphene. Alternative and adjunctive treatments have been developed such as tamoxifen, dexamethasone, and bromocriptine. Objectives To determine the relative effectiveness of anti-oestrogen agents alone or in combination with other medical therapies in women with subfertility associated with anovulation, possibly caused by polycystic ovarian syndrome (PCOS). Search strategy A search was conducted using the Cochrane Menstrual Disorders and Subfertility Group Trials Register (May 2009), CENTRAL (The Cochrane Library 2009, Issue 2), MEDLINE (1966 to May 2009), and EMBASE (1980 to May 2009) for identification of relevant randomised controlled trials (RCTs). The United Kingdom National Institute for Clinical Excellence (NICE) guidelines and the references of relevant reviews and RCTs were searched. Selection criteria RCTs comparing oral anti-oestrogen agents for ovulation induction (alone or in conjunction with medical therapies) in anovulatory subfertility were considered. Insulin sensitising agents, aromatase inhibitors, and hyperprolactinaemic infertility were excluded. Data collection and analysis Data extraction and quality assessment were done independently by two review authors. The primary outcome was live birth; secondary outcomeswere pregnancy, ovulation, miscarriage, multiple pregnancy, overstimulation, ovarian hyperstimulation syndrome, andwomen reported adverse effects. Main results This is a substantive update of a previous review. Fifteen RCTs were included. One trial reported live birth. Miscarriage, multiple pregnancy rates and adverse events were poorly reported. Clomiphene was effective in increasing pregnancy rate compared to placebo (OR 5.8, 95% CI 1.6 to 21.5) as was clomiphene plus dexamethasone treatment (OR 9.46, 95% CI 5.1 to 17.7) compared to clomiphene alone. No evidence of a difference in effect was found between clomiphene versus tamoxifen or clomiphene in conjunction with human chorionic gonadotrophin (hCG) versus clomiphene alone. The remaining results had only one study in each comparison. A significant improvement in the pregnancy rate was reported for clomiphene plus combined oral contraceptives versus clomiphene alone. No evidence of a difference in effect on pregnancy rate was found with any of the other comparisons. Authors' conclusions This review shows evidence supporting the effectiveness of clomiphene citrate and clomiphene in combination with dexamethasone for pregnancy rate only. There is limited evidence on the effects of these drugs on outcomes such as miscarriage. Evidence in favour of these interventions is flawed due to the lack of evidence on live births.
引用
收藏
页数:66
相关论文
共 77 条
  • [1] Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome
    Al-Omari, WR
    Sulaiman, WR
    Al-Hadithi, N
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2004, 85 (03) : 289 - 291
  • [2] [Anonymous], 2004, FERT ASS TREATM PEOP
  • [3] [Anonymous], 2006, INT J FORENSIC PSYCH
  • [4] [Anonymous], HUMAN REPROD ABSTRAC
  • [5] [Anonymous], MIDDLE E FERTILITY S
  • [6] [Anonymous], FERTILITY STERILI S1
  • [7] EFFECTS OF CLOMIPHENE CITRATE ON EPISODIC LUTEINIZING-HORMONE SECRETION THROUGHOUT THE MENSTRUAL-CYCLE
    ARCHER, DF
    HOFMANN, G
    BRZYSKI, R
    ROSS, B
    SCOTT, RT
    PHILPUT, CB
    OEHNINGER, S
    WARE, JC
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1989, 161 (03) : 581 - 592
  • [8] OVULATION INDUCTION WITH A SINGLE-BLIND TREATMENT REGIMEN COMPARING NALTREXONE, PLACEBO AND CLOMIPHENE CITRATE IN WOMEN WITH SECONDARY AMENORRHEA
    ARMEANU, MC
    MOSS, RJ
    SCHOEMAKER, J
    [J]. ACTA ENDOCRINOLOGICA, 1992, 126 (05): : 410 - 415
  • [9] Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation
    Atay, V
    Cam, C
    Muhcu, M
    Cam, M
    Karateke, A
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2006, 34 (01) : 73 - 76
  • [10] Aygen EM, 2007, ERCIYES MED J, V29, P195